CENTRO DE IMAGEM DIAGNOSTICA S.A. . (“Company” or “Alliar”) (B3: AALR3), pursuant to art. 157, §4, of Law no. 6,404, of December 15, 1976, as amended, and the provisions of CVM Resolution n. 44, of August 23, 2021, in continuity to the Material Fact disclosed on February 14, 2023, hereby informs its shareholders and the market in general that it has received, on this date, Official Letter no. 43/2023/CVM/SER/GER-1, the entire content of which is attached to this Material Fact, informing about the decision of the Securities Registration Superintendence regarding the rejection of the application for registration of the tender offer for the acquisition of shares by sale of control of the Company presented by Fonte de Saúde FIP Multiestratégia (“Offeror”).
The Company will pursue with the Offeror to obtain information regarding the measures that will be adopted in view of the rejection and the next steps and will keep the market duly updated regarding the developments of the matter.
São Paulo, February 24th, 2023
To access the full document, click here.
Pedro Aparicio
CFO & Investor Relations Director
E-mail: ri@alliar.com
